๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shijiazhuang
Clinical trial register · China

Clinical Trials in Shijiazhuang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hebei Medical University Fourth Hospital43 Novartis Pharmaceuticals12 BeOne Medicines9 Beijing InnoCare Pharma Tech Co., Ltd.8 Bristol-Myers Squibb8
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shijiazhuang

341 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
2,380
Hefei, Beijing, Shenzhen, Guangzhou, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2026-12-16
Not yet open
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07823270Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
33
Shijiazhuang
2026-10
Not yet open
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
280
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2026-10
Not yet open
Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
NCT07828899STOMACH NEOPLASM, Robotic Surgical Procedures
First Affiliated Hospital of Wenzhou Medical University
Not applicable
212
Shijiazhuang, Jinan, Wenzhou, Beijing, Chongqing
2026-10
Not yet open
Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation
NCT07774897Sleep Disturbance, Fatigue Syndrome, Chronic, Endocrine Disorder, Glucose Metabolism Disorder
Hepatopancreatobiliary Surgery Institute of Gansu Province
Not applicable
400
Lanzhou, Shijiazhuang, Xiangyang, รœrรผmqi, Kunming
2026-09-30
Not yet open
Renal Oxygenation-Guided AKI Reduction Trial
NCT07816640Acute Kidney Injury, Hepatectomy
Chinese PLA General Hospital
Not applicable
1,200
Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2026-09-20
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459Idiopathic Pulmonary Fibrosis
InSilico Medicine Hong Kong Limited
Phase 3
320
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Haikou, Shijiazhuang
2026-09-09
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155Systemic Lupus Erythematosus (SLE)
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Shenzhen, Zhongshan, Guilin, Liupanshui, Handan, Shijiazhuang, Changde, Changsha
2026-09-01
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
1,212
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2026-09-01
Not yet open
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT07792954Obesity, Overweight
Pfizer
Phase 3
300
Hefei, Beijing, Chongqing, Huizhou, Hengshui, Shijiazhuang, Harbin, Luoyang
2026-09-01
Not yet open
Guided Laminectomy With Augmented Duroplasty for Acute Traumatic Spinal Cord Injury
NCT07733401Spinal Cord Injury, Acute Spinal Cord Injury (SCI)
Xuanwu Hospital, Beijing
Not applicable
80
Beijing, Guangzhou, Maoming, Cangzhou, Shijiazhuang, Chifeng, Dezhou, Jinan
2026-09
Not yet open
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
NCT07745257HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
Novo Nordisk A/S
Phase 3
1,778
Hefei, Beijing, Chongqing, Shenzhen, Cangzhou, Langfang, Shijiazhuang, Kaifeng
2026-08-24
Recruiting
Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
NCT07711262Seasonal Allergic Rhinitis
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
Phase 3
550
Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Baotou, Chifeng, Yinchuan, Jinan
2026-08-18
Recruiting
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma
NCT07744932Oligometastatic Clear Cell Renal Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
48
Shijiazhuang
2026-08-15
Recruiting
Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
NCT07678931Seasonal Allergic Rhinitis (SAR)
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
136
Beijing, Langfang, Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Zhengzhou, Baotou
2026-08-13
Not yet open
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjรถgren's Syndrome
NCT07727486Primary Sjรถgren's Syndrome
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
240
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Changsha, Zhuzhou
2026-08
Recruiting
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria
NCT07512596Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
48
Bengbu, Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Zhuhai, Shijiazhuang
2026-07-21
Recruiting
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
NCT07596784Generalized Myasthenia Gravis, gMG
Alexion Pharmaceuticals, Inc.
Phase 3
20
Beijing, Changchun, Fuzhou, Jinan, Shanghai, Shijiazhuang, Taiyuan, Tianjin
2026-07-20
Recruiting
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT07557420NMOSD, Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.
Phase 3
19
Beijing, Chengdu, Dongguan, Jinan, Shanghai, Shijiazhuang, Taiyuan, Wenzhou
2026-07-20
Not yet open
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-07-16
Not yet open
A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions
NCT07702656High-grade Cervical Intraepithelial Lesions
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
175
Shijiazhuang
2026-07-10
Recruiting
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
NCT07586124Head and Neck Squamous Cell Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
80
Beijing, Fuzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changsha
2026-07-06
Not yet open
Zishen Yutai Pill for Patients With Recurrent Implantation Failure
NCT07641088Recurrent Implantation Failure
Peking University Third Hospital
Not applicable
878
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Nanjing, Xi'an
2026-07-01
Not yet open
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
NCT07697040Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 1
12
Shijiazhuang
2026-07-01
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
NCT07717905Chronic Spontaneous Urticaria
Bambusa Therapeutics
Phase 1/2
48
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jinzhou, Wuxi, Taiyuan, Xiโ€™an
2026-06-29
Not yet open
A Phase โ…ข Clinical Study of SNA02-48 Injection
NCT07633119Tetanus
Sinovac Life Sciences Co., Ltd.
Phase 3
600
Fuyang, Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Shijiazhuang
2026-06-28
Recruiting
Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
NCT07817108Varicella-zoster Virus
Suzhou Abogen Biosciences Co., Ltd.
Phase 3
18,000
Jinan, Nanning, Shijiazhuang, Zhejiang
2026-06-27
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
NCT07619287Myeloid Malignancy
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Recruiting
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
NCT07593248Lung Cancer
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
NCT07551427Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
51
Hefei, Fuzhou, Guangzhou, Nanning, Cangzhou, Chengde, Shijiazhuang, Xingtai
2026-06-18
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Nanning, Shijiazhuang, Wuhan, Changsha, Nanjing
2026-06-18
Recruiting
Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities
NCT07781124End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Vantive Health LLC
Observational
750
Beijing, Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-06-17
Recruiting
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
NCT07552402Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Harbin Medical University
Not applicable
150
Shijiazhuang, Harbin, Qiqihar, Baotou, Dalian, Hangzhou
2026-06-10
Not yet open
A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction
NCT07607210Siewert Type II Adenocarcinoma of the Esophagogastric Junction
Hebei Medical University Fourth Hospital
Phase 2
38
Shijiazhuang
2026-06-01
Recruiting
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT07489573Hidradenitis Suppurativa (HS)
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Shijiazhuang, Chengdu, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2026-06-01
Recruiting
Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT06993506HER2-negative Breast Cancer, Recurrence, Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
644
Beijing, Changzhou, Chongqing, Guangzhou, Huai'an, Ningbo, Shijiazhuang, Zhuzhou
2026-05-23
Recruiting
A Study of SKB571 in Participants With Gastrointestinal Tumors
NCT07564466Gastrointestinal Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin, Luoyang
2026-05-20
Not yet open
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
NCT07585279Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
Hebei Medical University Fourth Hospital
Phase 2/3
408
Shijiazhuang
2026-05-20
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
Beijing Anzhen Hospital
Not applicable
658
Beijing, Fuzhou, Zhangzhou, Nanning, Langfang, Shijiazhuang, Xingtai, Harbin
2026-05-12
Recruiting
A Phase โ…ก/โ…ข Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
NCT07462143Colorectal (Colon or Rectal) Cancer
RemeGen Co., Ltd.
Phase 2/3
80
Beijing, Chongqing, Fuzhou, Meizhou, Nanjing, Shijiazhuang, Zhengzhou, Wuhan
2026-05-12
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Recruiting
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT07379047GIST - Gastrointestinal Stromal Tumor, Advanced
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3
255
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Shijiazhuang
2026-05-11
Not yet open
Magnesium-Titanium Hybrid Intramedullary Nail System For Long Bone Fractures
NCT07569575Tibial Fracture, Femoral Fracture, Humeral Fracture
HuaMg Perfection Med Tech (Suzhou) Co., Ltd.
Not applicable
160
Xicheng, Luoyang, Shijiazhuang, Xi'an, Xuhui
2026-05-01
Not yet open
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
NCT07528898Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2
100
Shijiazhuang
2026-05
Recruiting
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
NCT07450599High-risk Localized Prostate Cancer
Bayer
Phase 2
250
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2026-04-27
Recruiting
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
NCT07440537Cutaneous Lupus Erythematosus (CLE)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
105
Hefei, Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Zhengzhou
2026-04-27
By invitation
Phase Ib Trial of Injectable RAB001 for Knee Osteoarthritis
NCT07652372Knee Osteoarthritis
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
Phase 1
60
Beijin, Shijiazhuang
2026-04-16
Recruiting
Medeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis
NCT07542938Symptomatic Intracranial Atherosclerotic Stenosis
Xuanwu Hospital, Beijing
Not applicable
264
Beijing, Fuzhou, Shijiazhuang, Harbin, Nanyang, Zhengzhou, Baotou, Xi'an
2026-04-15
Recruiting
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
NCT07390383Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
110
Beijing, Shijiazhuang, Jinan, Qingdao, Taiyuan, Tianjin
2026-04-13
Recruiting
Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)
NCT07389460Acute Ischemic Stroke
First Affiliated Hospital Xi'an Jiaotong University
Phase 3
820
Lanzhou, Shijiazhuang, Zhengzhou, Loudi, Dalian, Xining, Xi'an, Taiyuan
2026-04-07
Active, closed
A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Cascade Pharmaceuticals, Inc
Phase 2
130
Hefei, Guangzhou, Shijiazhuang, Nanjing, Shanghai, Hangzhou, Ningbo, Wenzhou
2026-04-02
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Shijiazhuang, Luoyang, Nanjing, Jinan, Chengdu
2026-04-01
Not yet open
A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke
NCT06459427Brain Stem Hemorrhage, Robotic Surgical Procedures
Yanbing Yu
Not applicable
142
Beijing, Shijiazhuang
2026-04
Not yet open
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion
NCT07487545Healthy
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
52
Shijiazhuang
2026-03-31
Not yet open
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase โ…ก Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT07465120Moderate to Severe Atopic Dermatitis
Dermavon Holdings Limited
Phase 2
160
Beijing, Fuzhou, Guangzhou, Shenzhen, Haikou, Shijiazhuang, Tangshan, Zhengzhou
2026-03-20
Recruiting
Efficacy and Mechanisms of Escitalopram in Drug-Naรฏve First-Episode Major Depressive Disorder
NCT07480525Depression - Major Depressive Disorder
Peking University
Not applicable
200
Beijing, Baoding, Shijiazhuang, Shenyang, Jinan
2026-03-20
Recruiting
Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
NCT07398859Seasonal Allergic Rhinitis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
300
Beijing, Chongqing, Baoding, Cangzhou, Langfang, Shijiazhuang, Zhangjiakou, Zhengzhou
2026-03-19
Recruiting
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
NCT07412691Skin Diseases
BeOne Medicines
Phase 1
98
Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai
2026-03-19
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487Moderate to Severe Asthma
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
195
Anqing, Suzhou, Beijing, Chongqing, Lanzhou, Shijiazhuang, Tangshan, Xingtai
2026-03-10
Recruiting
CAS for Stenosis With High-risk Features for CEA
NCT07370246Carotid Artery Stenosis, Carotid Artery Stenting
Beijing Tiantan Hospital
Not applicable
212
Beijing, Chongqing, Nanning, Guiyang, Shijiazhuang, Xingtai, Wuhan, Hohhot
2026-03-06
Not yet open
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
NCT07432854Moderate to Severe Plaque Psoriasis
Dermavon Holdings Limited
Phase 2/3
540
Bengbu, Wuhu, Guangzhou, Chengde, Handan, Shijiazhuang, Harbin, Nanyang
2026-03-03
Recruiting
DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
NCT07401173Gastric Cancer (Diagnosis), Postoperative Complications
Qun Zhao
Observational
500
Shijiazhuang
2026-03-01
Recruiting
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
NCT07448077Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
Hebei Medical University Fourth Hospital
Phase 2
128
Shijiazhuang
2026-03-01
Recruiting
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07327229Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited
Phase 1/2
132
Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Langfang, Shijiazhuang, Anyang
2026-02-27
Not yet open
The Auxiliary Effect of Artificial Intelligence in the Detection of Precancerous Lesions in Proximal Colon Cancer
NCT07338643Abdominal Pain, Black Stools, Constipation, Diarrhea
Limian Er
Observational
1,200
Shijiazhuang
2026-02-26
Not yet open
Evaluate Recombinant Human Serum Albumin From Oryza Sativa In Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment
NCT07435922Hypoalbuminemia, Hypovolemia
Healthgen Biotechnology Corp.
Observational
2,000
Shijiazhuang
2026-02-24
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
NCT07378527Chronic Spontaneous Urticaria (CSU)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
344
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang
2026-02-13
Not yet open
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
NCT07410611Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
Hebei Medical University Fourth Hospital
Phase 2
84
Shijiazhuang
2026-02-10
Not yet open
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
NCT07375979Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Recruiting
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
NCT07401199Gastric Cancer (GC), Locally Advanced Gastric Cancer
Qun Zhao
Observational
2,000
Fuyang, Cangzhou, Hengshui, Xingtai, Wuhan, Yichang, Baoding, Shijiazhuang
2026-02-05
Recruiting
Effect of Intrauterine Insemination on Subsequent Pregnancy Outcomes in Couples With Unexplained Pregnancy Loss: A Multicenter, Open-label, Randomized Controlled Trial
NCT07759609Unexplained Pregnancy Loss
Lanzhou University Second Hospital
Not applicable
558
Beijing, Lanzhou, Shijiazhuang
2026-01-27
Recruiting
Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study
NCT07669493MACE, Arrhythmia, Pericardial Effusion and Survival
Hebei Medical University Fourth Hospital
Observational
150
Shijiazhuang
2026-01-17
Active, closed
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
NCT07266090SLE - Systemic Lupus Erythematosus
Viatris Pharmaceuticals Co., Ltd.
Phase 2
15
Guangzhou, Shijiazhuang, Luoyang, Zhengzhou, Jiujiang, Nanchang, Beijing
2026-01-14
Recruiting
68Ga-BCMA PET/CT in Multiple Myeloma
NCT07319897Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
Peking University First Hospital
Phase 2/3
300
Beijing, Shijiazhuang, Jilin City
2025-12-25
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
ArriVent BioPharma, Inc.
Phase 3
480
Beijing, Xiamen, Foshan, Shantou, Shijiazhuang, Harbin, Luoyang, Xinxiang
2025-12-17
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Peking University
Phase 2
106
Shijiazhuang, Harbin, Zhengzhou, Nanjing, Xi'an, Qingdao, Taiyuan, Chengdu
2025-12-15
Active, closed
A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
NCT07293065Herpes Zoster
MAXVAX Biotechnology Limited Liability Company
Phase 3
12,000
Shijiazhuang, Zhengzhou, Wuhan, Kunming
2025-12-15
Not yet open
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
NCT07246317Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
188
Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing
2025-12-15
Recruiting
Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
NCT07262645Alzheimer s Disease
Danyang Huichuang Medical Equipment Co., Ltd.
Phase 3
320
Beijing, Shijiazhuang, Baotou, Suzhou, Xi'an, Shanghai, Taiyuan, Tianjin
2025-12-15
Not yet open
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score โ‰ค10
NCT07304258Gastric Cancer Peritoneal Metastases
Hebei Medical University
Phase 2
30
Shijiazhuang
2025-12-12
Recruiting
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
NCT07302360Colitis, Ulcerative
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shijiazhuang, Tianjin
2025-12-11
Recruiting
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .
NCT07242300Upper Limb Spasticity (ULS)
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
207
Beijing, Shijiazhuang, Luoyang, Zhengzhou, Changsha, Huai'an, Suzhou, Pingxiang
2025-12-11
Recruiting
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
NCT07265570Ulcerative Colitis
InSilico Medicine Hong Kong Limited
Phase 2
80
Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang
2025-12-10
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Not yet open
A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
NCT07292896Healthy Adults, Pulmonary Hypertension, Tricuspid Regurgitation, Heart Failure
First Hospital of China Medical University
Observational
2,640
Chongqing, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xiangyang, Changchun
2025-12
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
Robot-Assisted vs Manual Transradial Cerebral Angiography
NCT07696936Angiography, Digital Subtraction, Robot-assisted Therapy
The First Hospital of Hebei Medical University
Not applicable
156
Shijiazhuang
2025-11-30
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha
2025-11-27
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Recruiting
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
NCT07208058Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
Summit Therapeutics
Phase 3
600
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Haikou, Shijiazhuang, Harbin
2025-11-18
Recruiting
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection
NCT07241923Healthy Subjects (HS)
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1
48
Shijiazhuang
2025-11-15
Recruiting
Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
NCT07277907Slow Transit Constipation, Pharmacotherapy
Third Military Medical University
Phase 3
346
Bishan, Hechuan, Shapingba, Yuzhong, Lanzhou, Shijiazhuang, Harbin, Wuhan
2025-11-13
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
IBI351 Plus Cetuximab ฮฒ in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07198841Lung Cancer (Non-Small Cell)
Guangdong Association of Clinical Trials
Phase 2
48
Guangzhou, Beijing, Foshan, Nanchang, Nanning, Shijiazhuang
2025-11-03
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440Fabry Disease
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Rows per page Showing 1–100 of 341
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shijiazhuang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 341 of those studies with a site in Shijiazhuang.

How many clinical trials are recruiting in Shijiazhuang?

209 of the 341 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 52 have not yet opened recruitment, 75 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shijiazhuang), 341 studies
PhaseStudiesRecruitingShare
Phase 31035330.2%
Phase 2804923.5%
Observational473513.8%
Not applicable422612.3%
Phase 123146.7%
Phase 1/217145%
Phase 417115%
Phase 2/31163.2%
Phase EARLY_PHASE1110.3%

Most active sponsors

Lead sponsors with the most studies (Shijiazhuang)
Lead sponsorStudiesRecruiting
Hebei Medical University Fourth Hospital4329
Novartis Pharmaceuticals124
BeOne Medicines98
Beijing InnoCare Pharma Tech Co., Ltd.86
Bristol-Myers Squibb82
Pfizer86
AbbVie70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.65
Merck Sharp & Dohme LLC62
Qun Zhao64
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.